Methods of treating gastrointestinal stromal tumors
AssigneeDeciphera Pharmaceuticals, LLC
InventorsRodrigo Ruiz Soto, Oliver Rosen, Jama Pitman
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to methods of treating gastrointestinal stromal tumors to a subject in need thereof, comprising administering to the subject a therapeutically effective amount of ripretinib or a pharmaceutically acceptable salt thereof.
Claims14
A method of treating a patient suffering from an advanced gastrointestinal stromal tumor, comprising:
- orally administering to the patient daily three tablets each comprising 50 mg ripretinib, wherein the patient's tumor has progressed from:
- a first line administration of imatinib, a second line administration of sunitinib, and a third line administration of regorafenib, and wherein the treatment provides more than 3 months of progression free survival in patients, as determined by mRECIST 1.1, after at least 42 days of the daily ripretinib administration.
A method of treating a patient suffering from an advanced gastrointestinal stromal tumor, comprising:
- orally administering to the patient a 150 mg a once daily or twice daily dose of ripretinib, wherein the patient has previously been administered imatinib before administration of the ripretinib, and wherein the treatment provides more than 3 months of progression free survival in patients as determined by mRECIST 1.1, after at least one cycle of 42 days of the daily ripretinib administration.
A method of treating a patient suffering from an advanced gastrointestinal stromal tumor with a wild-type KIT mutation, comprising:
- orally administering to the patient a 150 mg ripretinib daily or twice daily, wherein the patient has previously been administered three or more kinase inhibitors before administration of the ripretinib, and where one of the previously administered kinase inhibitors is imatinib, and wherein the treatment provides more than 6 months of progression free survival in patients, as determined by mRECIST 1.1, after at least one cycle of 42 days of the daily ripretinib administration.
A method of treating a patient suffering from an advanced gastrointestinal stromal tumor, comprising:
- orally administering to the patient a 150 mg daily dose of ripretinib, wherein the patient's tumor has progressed from at least 4 lines of prior therapy, where the first line of prior therapy is imatinib, and wherein the treatment provides about 15 months survival in patients after at least 42 days of the daily ripretinib administration.
Dependencies are inferred from the claim text.